Medicure (TSXV:MPH) 5-Year EBITDA Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Medicure 5-Year EBITDA Growth Rate?

Medicure's EBITDA per Share for the three months ended in Dec. 2023 was C$-0.10.

During the past 12 months, Medicure's average EBITDA Per Share Growth Rate was -62.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medicure was 66.50% per year. The lowest was -58.80% per year. And the median was -8.60% per year.

Competitive Comparison of Medicure's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicure's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicure's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Medicure's 5-Year EBITDA Growth Rate falls into.

Medicure 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Medicure (TSXV:MPH) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Medicure 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Medicure's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicure (TSXV:MPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicure Inc (TSXV:MPH) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

MCUJF:USA NGQ1:Germany

Address

2 - 1250 Waverley Street, Winnipeg, MB, CAN, R3T 6C6

Website

https://www.medicure.com

Medicure Inc is a biopharmaceutical company. It is involved in the research, clinical development, and commercialization of human therapeutics for the United States hospital market. Further, it also operates a specialty pharmacy in the United States of America. The company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and developing its e-commerce and mail order pharmaceutical business. The company operates in two segments namely, Marketing and distribution of commercial products and, Retail and mail order pharmacy. The majority of the company's revenue is generated from the marketing and distribution of the commercial products segment.

Medicure (TSXV:MPH) Headlines

No Headlines